Vascular Biology and Metabolism (VAM)

< Back

Overview

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

Publications

248
total
1470
impact factor
5.93
average impact factor

Group Leader: Anna Rosell Novel

This 2019 in prevention of stroke and dementia we have focused on identifying new clinical and biological markers associated with small vessel disease progression in high-risk patients. The biomarkers and neuroprotection line has initiated a project (BIO-TARGETS) to elucidate whether some of the biomarkers we discovered to predict stroke outcome might become therapeutic targets used alone or in combination (COMBO-4-STROKE). Cerebral beta-amyloid studies haves focused on deepening into the mechanisms by which certain apoliproproteins act on the transport and metabolism of beta-amyloid using animal models and human samples from patients with Cerebral Amyloid Angiopathy or Alzheimer’s Disease. In stroke Neurorepair we have investigated biomarkers of recovery in the SMARRTS stroke cohort of patients under rehabilitation, investigated the effect of Diesel exhaust particles in a preclinical model of stroke and used new nanomaterials for brain drug delivery and imaging.

VHIR Annual Report 2019